[go: up one dir, main page]

BRPI0812807A2 - Método para a produção de um medicamento que contem tadafila - Google Patents

Método para a produção de um medicamento que contem tadafila

Info

Publication number
BRPI0812807A2
BRPI0812807A2 BRPI0812807-3A2A BRPI0812807A BRPI0812807A2 BR PI0812807 A2 BRPI0812807 A2 BR PI0812807A2 BR PI0812807 A BRPI0812807 A BR PI0812807A BR PI0812807 A2 BRPI0812807 A2 BR PI0812807A2
Authority
BR
Brazil
Prior art keywords
tadaphil
production
medication containing
medication
containing tadaphil
Prior art date
Application number
BRPI0812807-3A2A
Other languages
English (en)
Inventor
Rainer Alles
Julia Schulze Nahrup
Katrin Rimkus
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of BRPI0812807A2 publication Critical patent/BRPI0812807A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0812807-3A2A 2007-06-22 2008-06-23 Método para a produção de um medicamento que contem tadafila BRPI0812807A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028869A DE102007028869A1 (de) 2007-06-22 2007-06-22 Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
PCT/EP2008/005066 WO2009000493A1 (de) 2007-06-22 2008-06-23 Verfahren zur herstellung eines arzneimittels enthaltend tadalafil

Publications (1)

Publication Number Publication Date
BRPI0812807A2 true BRPI0812807A2 (pt) 2014-12-02

Family

ID=39797930

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812807-3A2A BRPI0812807A2 (pt) 2007-06-22 2008-06-23 Método para a produção de um medicamento que contem tadafila

Country Status (14)

Country Link
US (2) US9238007B2 (pt)
EP (1) EP2170281A1 (pt)
JP (1) JP5443344B2 (pt)
KR (1) KR101525021B1 (pt)
CN (1) CN101720221A (pt)
AU (1) AU2008267431C1 (pt)
BR (1) BRPI0812807A2 (pt)
CA (1) CA2691667C (pt)
DE (1) DE102007028869A1 (pt)
EA (1) EA022100B1 (pt)
IL (1) IL202783A (pt)
UA (1) UA95374C2 (pt)
WO (1) WO2009000493A1 (pt)
ZA (1) ZA200908965B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
DE102010017463B4 (de) * 2010-06-18 2014-02-20 Eickhoff Antriebstechnik Gmbh Planetenbolzen, Planetenträger, Planetengetriebe und Verfahren zur drehfesten Befestigung eines Planetenbolzens an einen Planetenträger
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014125352A1 (en) * 2013-02-14 2014-08-21 Aurobindo Pharma Limited Pharmaceutical compositions comprising tadalafil
US11116769B2 (en) 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
MX373722B (es) * 2013-04-11 2020-04-13 Ctc Bio Inc Forma farmaceutica en pelicula que contiene tadalafilo en forma de base libre con polimero de polietilenglicol y/o polimero de vinil pirrolidona como estabilizante de dispersion.
MX2015016865A (es) * 2013-07-05 2016-04-07 Synthon Bv Composicion farmaceutica que comprende una dispersion solida de tadalafilo.
WO2015000853A1 (en) * 2013-07-05 2015-01-08 Synthon B.V. Pharmaceutical composition comprising a solid dispersion of tadalafil
KR101538985B1 (ko) * 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
CN104523644B (zh) * 2015-01-27 2017-06-20 江苏联环药业股份有限公司 一种快速溶出的氯雷他定片剂及其制备工艺
KR20160138796A (ko) 2015-05-26 2016-12-06 삼아제약 주식회사 타달라필을 유효성분으로 함유하는 신규한 속효성 세립제형
KR101634382B1 (ko) 2015-10-20 2016-06-28 미래제약 주식회사 타다라필 경구용 액제
US10624888B2 (en) 2016-03-31 2020-04-21 SpecGx LLC Extended release, abuse deterrent dosage forms
EA028561B1 (ru) * 2016-12-28 2017-11-30 Тева Фармасьютикал Индастриз, Лтд. Твердые лекарственные формы тадалафила
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
CN112206213A (zh) * 2020-10-26 2021-01-12 广州汇元医药科技有限公司 一种枸橼酸西地那非组合物及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU171662B (hu) 1975-07-18 1978-02-28 Richter Gedeon Vegyeszet Sposob poluchenija novykh, opticheski aktivnykh proizvodnykh apovinkaminola i ikh kislotnykh adduktov
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0297866A3 (en) 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
CA2346350C (en) 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
IL135817A0 (en) 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
UA71629C2 (en) 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
WO2001008687A1 (en) * 1999-08-03 2001-02-08 Lilly Icos Llc Beta-carboline pharmaceutical compositions
MXPA02006079A (es) 1999-12-20 2004-08-23 Nicholas J Kerkhof Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN100346832C (zh) 2002-02-07 2007-11-07 法玛西雅公司 经粘膜递送的药物剂型
US20080226723A1 (en) 2002-07-05 2008-09-18 Celonova Biosciences, Inc. Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same
AU2003304236A1 (en) 2002-08-30 2005-01-13 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
US20050019641A1 (en) 2003-06-18 2005-01-27 Toshiyuki Aoyama Fuel tank for fuel-cell and fuel cell system
WO2005065308A2 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060276442A1 (en) 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MX2007010433A (es) * 2005-02-25 2007-10-11 Teva Pharma Tadafil que tiene un tamano de particula grande y un proceso para la preparacion del mismo.
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
WO2007002125A1 (en) 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20070009589A1 (en) 2005-07-07 2007-01-11 Kandarapu Raghupathi Extended release compositions
CN1742732A (zh) 2005-09-20 2006-03-08 杭州恒丰医药科技有限公司 西力士滴丸及其制备方法
CA2654902A1 (en) 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Solid compositions comprising tadalafil and at least one carrier
ES2405787T3 (es) 2007-04-25 2013-06-03 Teva Pharmaceutical Industries Ltd. Formas de dosificación solidas
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20090047330A1 (en) 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US7957504B2 (en) 2008-10-20 2011-06-07 Los Alamos National Security, Llc Method and apparatus for measuring enrichment of UF6
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
CN101741732B (zh) * 2009-11-30 2011-11-30 中国人民解放军国防科学技术大学 容延网络中网络节点存储器的扩展管理方法

Also Published As

Publication number Publication date
WO2009000493A1 (de) 2008-12-31
AU2008267431A1 (en) 2008-12-31
US20100179159A1 (en) 2010-07-15
KR20100052453A (ko) 2010-05-19
EP2170281A1 (de) 2010-04-07
JP2010530858A (ja) 2010-09-16
ZA200908965B (en) 2012-06-27
EA201070046A1 (ru) 2010-06-30
CA2691667A1 (en) 2008-12-31
US20160101103A1 (en) 2016-04-14
AU2008267431B2 (en) 2013-05-23
CN101720221A (zh) 2010-06-02
US9238007B2 (en) 2016-01-19
DE102007028869A1 (de) 2008-12-24
UA95374C2 (ru) 2011-07-25
IL202783A0 (en) 2010-06-30
EA022100B1 (ru) 2015-11-30
JP5443344B2 (ja) 2014-03-19
CA2691667C (en) 2014-10-28
AU2008267431C1 (en) 2013-09-26
IL202783A (en) 2017-01-31
KR101525021B1 (ko) 2015-06-04

Similar Documents

Publication Publication Date Title
BRPI0812807A2 (pt) Método para a produção de um medicamento que contem tadafila
BRPI0719843A2 (pt) Método para a produção de bisbenzoxazóis
BRPI0909427A2 (pt) resinas carregadas e método para a produção de resinas carregadas
BRPI0922710A2 (pt) método para a produção de plaquetas
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI0921381A2 (pt) método e dispositivo para a produção de um gás de síntese bruto.
BRPI0913848A2 (pt) processo para a fabricação de hidrocarbonetos de origem biológica
BRPI1013822A2 (pt) Método para síntese de um trissacarídeo.
BRPI0815138A2 (pt) Métodos e organismos para a produção acoplada a crescimento de 1,4-butanodiol
BR112012009974A2 (pt) método para produzir grândulos que compreendem um perticida
BRPI0820655A2 (pt) Processo e dispositivo de formação de gotas para a fabricação de pastilhas, bem como, processo para a fabricação de um fertilizante contendo enxofre
BRPI0720174A2 (pt) Processo para modificação da resistência de plantas a insetos através da utilização da técnica de rnai
BRPI0818049A2 (pt) Método para a preparação de nitratos orgânicos
BRPI0818541A2 (pt) Processo para a produção de um produto farmacêutico
BRPI0816589A2 (pt) Método para formar um artigo e artigo respirável
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0820108A2 (pt) Método para a produção de composto de carbonato
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BRPI0810991A2 (pt) Método para a produção de um composto de amida.
BRPI0807870A2 (pt) Método para a produção de um revestimento
BRPI0814824A2 (pt) Método e aparelho para a produção de um fundido
BRPI0923109A8 (pt) método para a produção de derivados de diamina
BRPI0821241A2 (pt) Processo para a produção de um composto orgânico marcado com flúor radioativo
BRPI0821837A2 (pt) Processo para a preparação de 6-substituídas-1-(2h)-isoquinolinonas
BRPI0915080A2 (pt) dispositivos, processos e métodos para a produção de ésteres de alquílicos inferiores

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]